Issued 2026-08-13 at $10.91 · now $10.66 (2026-08-13, −2.3% since)
Based on its own history, a month from the 2026-08-13 close, RGNX has typically landed between $7.91 and $14.67 — a range of −27.5% to +34.5% from the issuance price $10.91.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,721 overlapping 1 month windows · 2015-09-17 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($10.91) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where RGNX has typically landed a month from the 2026-08-13 close of $10.91 — the range is history, not a prediction.
- now $10.66 (-2.3%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $10.62 (-2.7%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $9.43–$11.81
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $7.91–$14.67
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-18 | −59.8% | −59.8% | +1.1% |
| 2020-02-13 | −53.3% | −53.3% | +0.0% |
| 2020-02-19 | −52.6% | −60.2% | +0.0% |
| 3 best | |||
| 2026-06-08 | +155.3% | +0.0% | +155.3% |
| 2026-06-05 | +150.5% | +0.0% | +150.5% |
| 2026-06-03 | +121.7% | −9.1% | +121.7% |
2,721 overlapping windows · 2015-09-17 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) (source, as of 2026-08-14)
- 2028-04-30 — Trial primary completion: Phase 3 primary completion: RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~11 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.